vs
Side-by-side financial comparison of Doximity, Inc. (DOCS) and Travere Therapeutics, Inc. (TVTX). Click either name above to swap in a different company.
Doximity, Inc. is the larger business by last-quarter revenue ($185.1M vs $129.7M, roughly 1.4× Travere Therapeutics, Inc.). On growth, Travere Therapeutics, Inc. posted the faster year-over-year revenue change (73.4% vs 9.8%). Over the past eight quarters, Travere Therapeutics, Inc.'s revenue compounded faster (77.0% CAGR vs 25.2%).
Doximity is an online networking service for medical professionals. Launched in 2010, the platform offers its members curated medical news, telehealth tools, and case collaboration.
Travere Therapeutics, Inc. is a global biopharmaceutical firm developing and commercializing innovative therapies for patients with rare, serious, life-threatening diseases. Its key segments cover rare nephrology, hepatology and metabolic disorders, serving markets across North America, Europe and other global regions.
DOCS vs TVTX — Head-to-Head
Income Statement — Q3 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $185.1M | $129.7M |
| Net Profit | $61.6M | — |
| Gross Margin | 89.9% | 98.0% |
| Operating Margin | 38.9% | -25.0% |
| Net Margin | 33.3% | — |
| Revenue YoY | 9.8% | 73.4% |
| Net Profit YoY | -18.1% | — |
| EPS (diluted) | $0.31 | $0.04 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $185.1M | $129.7M | ||
| Q3 25 | $168.5M | $164.9M | ||
| Q2 25 | $145.9M | $114.4M | ||
| Q1 25 | $138.3M | $81.7M | ||
| Q4 24 | $168.6M | $74.8M | ||
| Q3 24 | $136.8M | $62.9M | ||
| Q2 24 | $126.7M | $54.1M | ||
| Q1 24 | $118.1M | $41.4M |
| Q4 25 | $61.6M | — | ||
| Q3 25 | $62.1M | $25.7M | ||
| Q2 25 | $53.3M | $-12.8M | ||
| Q1 25 | $62.5M | $-41.2M | ||
| Q4 24 | $75.2M | — | ||
| Q3 24 | $44.2M | $-54.8M | ||
| Q2 24 | $41.4M | $-70.4M | ||
| Q1 24 | $40.6M | $-136.1M |
| Q4 25 | 89.9% | 98.0% | ||
| Q3 25 | 90.3% | 99.0% | ||
| Q2 25 | 89.2% | 98.7% | ||
| Q1 25 | 89.5% | 94.3% | ||
| Q4 24 | 91.6% | 96.6% | ||
| Q3 24 | 90.0% | 97.4% | ||
| Q2 24 | 89.3% | 96.2% | ||
| Q1 24 | 89.4% | 96.4% |
| Q4 25 | 38.9% | -25.0% | ||
| Q3 25 | 37.8% | 15.1% | ||
| Q2 25 | 37.4% | -11.1% | ||
| Q1 25 | 35.2% | -52.2% | ||
| Q4 24 | 47.4% | -81.2% | ||
| Q3 24 | 38.8% | -89.3% | ||
| Q2 24 | 36.4% | -125.1% | ||
| Q1 24 | 35.5% | -336.5% |
| Q4 25 | 33.3% | — | ||
| Q3 25 | 36.8% | 15.6% | ||
| Q2 25 | 36.5% | -11.1% | ||
| Q1 25 | 45.2% | -50.4% | ||
| Q4 24 | 44.6% | — | ||
| Q3 24 | 32.3% | -87.1% | ||
| Q2 24 | 32.7% | -130.1% | ||
| Q1 24 | 34.4% | -328.9% |
| Q4 25 | $0.31 | $0.04 | ||
| Q3 25 | $0.31 | $0.28 | ||
| Q2 25 | $0.27 | $-0.14 | ||
| Q1 25 | $0.31 | $-0.47 | ||
| Q4 24 | $0.37 | $-0.71 | ||
| Q3 24 | $0.22 | $-0.70 | ||
| Q2 24 | $0.21 | $-0.91 | ||
| Q1 24 | $0.20 | $-1.76 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $64.8M | $93.0M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $979.3M | $114.8M |
| Total Assets | $1.2B | $605.2M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $64.8M | $93.0M | ||
| Q3 25 | $169.2M | $110.9M | ||
| Q2 25 | $137.3M | $75.2M | ||
| Q1 25 | $209.6M | $61.9M | ||
| Q4 24 | $165.3M | $58.5M | ||
| Q3 24 | $184.2M | $36.4M | ||
| Q2 24 | $111.4M | $32.3M | ||
| Q1 24 | $96.8M | $43.3M |
| Q4 25 | $979.3M | $114.8M | ||
| Q3 25 | $1.1B | $73.6M | ||
| Q2 25 | $1.0B | $32.7M | ||
| Q1 25 | $1.1B | $32.8M | ||
| Q4 24 | $1.0B | $59.1M | ||
| Q3 24 | $961.2M | $-30.5M | ||
| Q2 24 | $913.6M | $15.1M | ||
| Q1 24 | $901.4M | $74.1M |
| Q4 25 | $1.2B | $605.2M | ||
| Q3 25 | $1.3B | $538.6M | ||
| Q2 25 | $1.2B | $555.3M | ||
| Q1 25 | $1.3B | $548.8M | ||
| Q4 24 | $1.2B | $594.1M | ||
| Q3 24 | $1.1B | $504.4M | ||
| Q2 24 | $1.1B | $551.1M | ||
| Q1 24 | $1.1B | $663.5M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $60.9M | $60.7M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | 0.99× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $60.9M | $60.7M | ||
| Q3 25 | $93.9M | $14.3M | ||
| Q2 25 | $62.1M | $5.0M | ||
| Q1 25 | $98.5M | $-42.2M | ||
| Q4 24 | $65.2M | $-35.7M | ||
| Q3 24 | $68.3M | $-42.5M | ||
| Q2 24 | $41.2M | $-40.2M | ||
| Q1 24 | $63.9M | $-119.0M |
| Q4 25 | — | — | ||
| Q3 25 | — | $14.2M | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | $-40.3M | ||
| Q1 24 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | — | 8.6% | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | -74.5% | ||
| Q1 24 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | — | 0.1% | ||
| Q2 25 | — | — | ||
| Q1 25 | 0.0% | — | ||
| Q4 24 | 0.0% | — | ||
| Q3 24 | 0.0% | 0.0% | ||
| Q2 24 | 0.0% | 0.2% | ||
| Q1 24 | 0.0% | 0.0% |
| Q4 25 | 0.99× | — | ||
| Q3 25 | 1.51× | 0.56× | ||
| Q2 25 | 1.16× | — | ||
| Q1 25 | 1.58× | — | ||
| Q4 24 | 0.87× | — | ||
| Q3 24 | 1.55× | — | ||
| Q2 24 | 1.00× | — | ||
| Q1 24 | 1.57× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
DOCS
| Subscription | $175.4M | 95% |
| Service Other | $9.7M | 5% |
TVTX
| FILSPARI | $103.3M | 80% |
| Tiopronin Products | $23.3M | 18% |
| License | $3.1M | 2% |
